Cargando…

Impact of the pneumococcal 10-valent vaccine on reducing hospitalization for community-acquired pneumonia in children

OBJECTIVE: To describe and analyze the occurrence of hospitalizations for community-acquired pneumonia in children before and after the pneumococcal 10-valent conjugate vaccine implementation into the National Immunization Program. METHODS: This is an ecological study that includes records of childr...

Descripción completa

Detalles Bibliográficos
Autores principales:	da Silva, Sandra Rodrigues, de Mello, Luane Marques, da Silva, Anderson Soares, Nunes, Altacílio Aparecido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade de Pediatria de São Paulo 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5176061/ https://www.ncbi.nlm.nih.gov/pubmed/27108092 http://dx.doi.org/10.1016/j.rppede.2016.03.008

Ejemplares similares

Analysis of factors associated with excess weight in school children
por: Pinto, Renata Paulino, et al.
Publicado: (2016)

Clinical and epidemiological characteristics of severe community-acquired pneumonia in children after introduction of the 10-valent pneumococcal vaccine
por: Lima, Eduardo JF, et al.
Publicado: (2015)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly
por: Kislaya, Irina, et al.
Publicado: (2019)

Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults
por: Isturiz, Raul, et al.
Publicado: (2015)

Associated factors with mammographic changes in women undergoing breast cancer screening
por: de Sant'Ana, Ricardo Soares, et al.
Publicado: (2016)

Effect of 10-Valent Pneumococcal Vaccine on Pneumonia among Children, Brazil
por: Afonso, Eliane Terezinha, et al.
Publicado: (2013)

Pneumococcal Carriage, Serotype Distribution, and Risk Factors in Children With Community-Acquired Pneumonia, 5 Years After Introduction of the 10-Valent Pneumococcal Conjugate Vaccine in Ethiopia
por: Negash, Abel Abera, et al.
Publicado: (2019)

Spatiotemporal distribution of acquired immunodeficiency syndrome incidence in Brazil between 2012 and 2016
por: Martinez, Edson Zangiacomi, et al.
Publicado: (2019)

23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae
por: Chandler, Thomas, et al.
Publicado: (2022)

Clinical response to antibiotics in indigenous versus non-indigenous children under 5 years old with community-acquired pneumonia in Otavalo, Ecuador
por: Matute, Susana Eulalia Dueñas, et al.
Publicado: (2020)

Direct Effect of 10-Valent Conjugate Pneumococcal Vaccination on Pneumococcal Carriage in Children Brazil
por: Andrade, Ana Lucia, et al.
Publicado: (2014)

Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain
por: Domínguez, Àngela, et al.
Publicado: (2017)

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
por: Shen, Ching-Fen, et al.
Publicado: (2021)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
por: Adamu, Aishatu L., et al.
Publicado: (2023)

Distribution of 13-Valent pneumococcal conjugate vaccine serotype streptococcus pneumoniae in adults 50 Years and Older presenting with community-acquired pneumonia in Israel
por: Regev-Yochay, Gili, et al.
Publicado: (2018)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
por: Hanquet, Germaine, et al.
Publicado: (2022)

Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan
por: Takeuchi, N., et al.
Publicado: (2020)

Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010–2015
por: Silva-Costa, Catarina, et al.
Publicado: (2018)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Comment on Chandler et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms 2022, 10, 560
por: Cossrow, Nicole, et al.
Publicado: (2022)

1104 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Immunogenicity in the Community Acquired Pneumonia Immunization Trial In Adults (CAPiTA)
por: Van Deursen, Anna M.M., et al.
Publicado: (2014)

The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial
por: Huijts, S.M., et al.
Publicado: (2018)

The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia
por: Shen, Ching-Fen, et al.
Publicado: (2020)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
por: Earnshaw, Stephanie R, et al.
Publicado: (2012)

Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia
por: ELEMRAID, M. A., et al.
Publicado: (2013)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
por: Ansaldi, Filippo, et al.
Publicado: (2020)

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design
por: McLaughlin, John M, et al.
Publicado: (2018)

Impact of 10-Valent Pneumococcal Conjugate Vaccine on Bacterial Meningitis in Madagascar
por: Andriatahirintsoa, Emilson Jean P R, et al.
Publicado: (2019)

The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji
por: Reyburn, R., et al.
Publicado: (2022)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
por: Kim, Hye-Young, et al.
Publicado: (2020)

Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules
por: Leach, Amanda Jane, et al.
Publicado: (2014)

Assessment of Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Kenyan Children
por: Ayieko, Philip, et al.
Publicado: (2013)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
por: Wasserman, Matthew, et al.
Publicado: (2018)

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands
por: Knol, Mirjam J., et al.
Publicado: (2015)

Community Care Administration of Spinal Deformities in the Brazilian Public Health System
por: Bressan-Neto, Mario, et al.
Publicado: (2017)

Pneumococcal colonization and severity of pneumonia in hospitalized Cambodian children following introduction of the 13-valent pneumococcal conjugate vaccine
por: Miliya, Thyl, et al.
Publicado: (2023)

Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children
por: Shiragami, Makoto, et al.
Publicado: (2014)

Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
por: Ghia, Canna J., et al.
Publicado: (2021)

Effectiveness of the 10-valent pneumococcal conjugate vaccine on pediatric pneumonia confirmed by ultrasound: a matched case–control study
por: Checkley, William, et al.
Publicado: (2022)

Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia
por: Endimiani, Andrea, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_4c1jn7svs50j451rvfh61la66m